Literature DB >> 25418715

First experience with therapy of severe forms of psoriasis with biosimilar infliximab.

M Tichy1, R Kopova1, J Sternbersky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25418715     DOI： 10.1111/jdv.12876

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  2 in total

1.  Biomedical and Market Issues Surrounding the Advent of Biosimilars.

Authors:  Abigail Cline; Jake E Turrentine
Journal:  Dermatol Ther (Heidelb)       Date:  2016-06-21

2.  Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab.

Authors:  Martin Tichy
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.